Delivery Order SPE2DB22D2108-SPE2DB25FU5LE
- Not listed
- The Defense Logistics Agency awarded a $1,088.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injectors. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion pharmaceutical prime vendor agreement running through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $13,172.65 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors with a completion date of April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $1,632.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp on May 5, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injectors (0.5 mL units). The contract was competitively awarded with no set-aside designation and maintains an ultimate completion date of May 6, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a $5,652.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors with an ultimate completion date of September 8, 2025. This non-set-aside contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's substantial Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $31,664.53 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen injectors (0.5 ml units), with completion scheduled for September 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,088.36 for Mounjaro 15 mg/0.5 mL pen injections on June 16, 2025, with an ultimate completion date of June 17, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at approximately $1...
- The Defense Logistics Agency awarded a $11,834.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors on July 14, 2025, with completion targeted for July 15, 2025. This non-set-aside competitive award will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $3,521.86 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors. This non-set-aside, firm fixed-price contract is scheduled for completion by August 14, 2025, with performance based in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a $5,441.80 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Mounjaro 2.5 mg/0.5 mL pen injectors (0.5 mL). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 13, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for Mounjaro 15 mg/0.5 mL pen injectors on August 22, 2025, with an ultimate completion date of August 25, 2025. This is a firm fixed-price, non-set-aside contract for delivery to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- SPE2DB22D2108Indefinite Delivery Contract
- SPE2DB22D2108-SPE2DB25FU5LEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,825.26 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 ml pen injectors on August 13, 2025, with completion scheduled for August 14, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through its DLA relationship, supplying medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military and veteran healthcare systems. Mounjaro is a diabetes management medication, consistent with AmerisourceBergen's portfolio of chronic disease treatments delivered through the DLA Medical Supply Chain. The delivery order carries no set-aside designation and reflects the company's established capability to fulfill federal pharmaceutical requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/13/25 |